Clinical Trial Update: Efficacy and Safety of RC28-E Versus Aflibercept [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing RC28-E to aflibercept for wet age-related macular degeneration; efficacy and safety data not yet available in the excerpt.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• RC28-E

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Wet Age-related Macular Degeneration | Phase 3 | Status: UNKNOWN